Avacta shares quadrupled in five years! Am I too late to buy?

Christopher Ruane thinks the incredible run of Avacta shares over the past few years may have room left to run. Should he buy?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

A senior woman sits up on the exam table at a doctors appointment. She is dressed casually in a blue sweater and has a smile on her face as she glances at the doctor. Her female doctor is wearing a white lab coat and seated in front of her as she takes notes on a tablet.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

If I had bought into Avacta (LSE: AVCT) five years ago, the value of my investment would have quadrupled. That is the sort of return many investors dream of. Have I missed the boat, or should I add some Avacta shares to my portfolio now?

Improving outlook

This week the company published its prelim results, and there were definitely some positive elements.

Revenue more than tripled. It is still fairly low at £9.6m, given that Avacta has a market capitalisation north of £300m. But the big jump reflected Avacta reaching certain milestones in its collaborative work with a couple of partners, resulting in cash payments. That suggests that the business is moving forward. Some of the revenue increase also resulted from the acquisition of a diagnostics company.

I see such developments as part of the foundation for longer-term revenue growth.

The company also reduced its adjusted loss before interest, tax, depreciation and amortisation (before non-cash and non-recurring items) by 30%.

But it is still substantial, at £15.1m. I also think that metric is so loaded with exclusions that it is not a useful measurement tool for an investor like me. The statutory loss from continuing operations moved up sharply, to almost £40m.

The company thinks that a “significant near-term value driver” will be clinical trials on the efficacy of a programme to reduce the systemic toxicities of some chemotherapy treatments. It announced yesterday that the first patient has been dosed in a US Phase One clinical study for that treatment.

Lots to prove

However, a lot rides on the ultimate outcome of those clinical trials. If they provide positive results of the treatment’s efficacy, I think Avacta shares could soar even from where they are today.

The reverse is also true, though. Failure in the costly trials could see the shares crash down to earth after their strong performance in recent years.

Meanwhile, cash burn is a concern for me. It ended last year with cash and cash equivalents of £42m. But cash has been going out the door fast. Last year, the business had operating cash outflows of £16m. Acquisition costs pushed investing net cash outflows to £25m.

The company has been able to raise cash. Selling more shares and bonds last year raised £61m, for example. But there is a risk of further shareholder dilution in future due to the company’s ongoing cash burn.

Are Avacta shares for me?

Given all this, it does not take me long to consider my own position as a potential investor.

I like the company’s prospects and, if clinical trial results are positive, reckon Avacta shares could keep soaring in coming years.

But the risks are simply too high for my tolerance, even if they are common when investing in biotech shares.

The company is heavily lossmaking. For now, a lot rides on a single product, concentrating the risk. There is no proven profitable model here yet, so I would be investing based on my hopes for the company’s drug pipeline, not its current performance.

That seems too risky for me. I shall not be purchasing any Avacta shares.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

C Ruane has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Man putting his card into an ATM machine while his son sits in a stroller beside him.
Investing Articles

The Barclays share price has soared 72% in 2024. Is it too late for me to buy?

I'm looking for a bank stock to buy in early 2025. The 2024 Barclays share price rise has made the…

Read more »

Investing Articles

2 lessons from the HSBC share price soaring 159% in four years

Christopher Ruane looks at the incredible performance of the HSBC share price in recent years and learns some lessons for…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

After a 2,342% rise, could this FTSE 250 stock keep going?

This FTSE 250 stock boasts a highly cash-generative business model and has been flying for years. Is it time to…

Read more »

Investing Articles

It’s up 70%, but the experts expect the IAG share price to climb still further

Why didn't I buy when I was convinced the IAG share price was likely to soar? And is there still…

Read more »

Businessman use electronic pen writing rising colorful graph from 2023 to 2024 year of business planning and stock investment growth concept.
Investing Articles

2 UK stocks with recovering profit margins

This writer considers a pair of UK stocks with very different share price trajectories following the pandemic. Would he buy…

Read more »

The flag of the United States of America flying in front of the Capitol building
Investing Articles

Will Trump’s tariffs squeeze this FTSE 100 giant’s profits?

Our writer looks at how the latest news around US tariffs might impact FTSE 100 company Diageo. Should he be…

Read more »

Investing Articles

Up 95%, is this FTSE winner the best high-yield star for me to buy now?

Do we have to choose between share price growth and high-yield dividends? In this case, over the past year, it…

Read more »

Asian Indian male white collar worker on wheelchair having video conference with his business partners
Investing Articles

2 dividend-paying FTSE shares that could benefit from the AI revolution

Our writer examines two dividend-paying FTSE shares and explains some of the opportunities and risks he sees in their exposure…

Read more »